Chymostatin
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Ki: 9.36 and 13.1 nM for chymotrypsin and chymase, respectively
Chymostatin is a chymotryptase-like serine proteases inhibitor.
Serine proteases are enzymes cleaving peptide bonds, in which serine plays as the nucleophilic amino acid. Serine proteases can be classfied into two broad categories: chymotrypsin-like (trypsin-like) or subtilisin-like.
In vitro: Chymostatin was found to be a potent inhibitor of human leucocyte chymotrypsin-like protease. Its affinity to the leucocyte protease was found to be much higher than its affinity to bovine pancreatic alpha-chymotrypsin. Chymsotatin also showed a weak inhibitory effect on the activity of human leucocyte elastase. In addition, the preincubation of chymostatin with 35SO2-4-labeled cartilage before the addition of the human chymotrypsin-like protease to the tissue could also inhibit 35SO2-4 release [1].
In vivo: The effect of chymostatin on C57BL/6J-dy dystrophic mice was studied. The locomotor activity of normal mice markedly increased, attaining a plateau at 8 weeks of age. Serum levels of creatine phosphokinase were much higher in dystrophic mice when compared with normal mice, and dystrophic mice also showed a reduced muscle protein content. When 3-week-old dystrophic mice received chymostatin at 1 mg/kg, the decrease in locomotor activity could be retarded, serum enzyme levels significantly decreased, and muscle protein content also obviously increased. In addition, the survival time of chymostatin-treated dystrophic mice was prolonged [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Feinstein, G. ,Malemud, C.J., and Janoff, A. The inhibition of human leucocyte elastase and chymotrypsin-like protease by elastatinal and chymostatin. Biochim.Biophys.Acta. 429(3), 925-932 (1976).
[2] Komatsu K, Matsui A, Satoh S. Beneficial effect of chymostatin on dystrophic mice. Exp Neurol. 1986 Jul;93(1):110-6.
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 607.7 |
Cas No. | 9076-44-2 |
Formula | C31H41O6N7 |
Solubility | ≤10mg/ml in DMSO |
Chemical Name | (2R,6R,9R,12R)-6-((R)-2-amino-3,4,5,6-tetrahydropyrimidin-4-yl)-2,12-dibenzyl-9-isobutyl-4,7,10,13-tetraoxo-3,5,8,11-tetraazatridecan-1-oic acid |
SDF | Download SDF |
Canonical SMILES | O=C(O)[C@H](NC(N[C@H]([C@H]1CCN=C(N)N1)C(N[C@H](CC(C)C)C(N[C@H](CC2=CC=CC=C2)C=O)=O)=O)=O)CC3=CC=CC=C3 |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
质量控制和MSDS
- 批次:
-
纯度 ≥ 95.00% (a mixture of A, B, C)
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)